Cytoreductive Surgery & Peritoneum ·
CRS + HIPEC provides significant benefits to HCC-PM patients, with 89.0% 1-year and 3-year OS rates. Some patients achieved prolonged PFS, enhancing treatment options for this challenging condition. Incorporating CRS + HIPEC into the treatment regimen is a strategic therapeutic choice for HCC-PM patients, supported by the study’s findings of extended survival outcomes.
Journal Article by Yan G, Zhang K, Yan L and Zhang Y in World J Surg Oncol
© 2024. The Author(s).
Summaries are written to help you decide what to read. They do not replace the full paper.
Free · 5 minutes a day
Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.
More in Cytoreductive Surgery & Peritoneum
In patients with gastric cancer and positive peritoneal lavage cytology or localized peritoneal metastasis, upfront chemotherapy followed by surgery yields better outcomes than surgery followed by chemotherapy.
Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.
Secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy improves survival for select patients with recurrent colorectal cancer peritoneal metastases.
